What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
In the case of Genentech Inc., nothing.
The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.
Study outcome won't sway company on eye drug
More than 200 million eggs are being recalled over fears of salmonella.
Rose Acre Farms of Seymour,...
Researchers in Germany have developed a blood test for Alzheimer's that detects the disease several years...
The Arizona state House of Representatives passed a bill that would require women seeking abortions to...
Omni Healthcare is suing wholesale drug distributor McKesson Corp. on behalf of the federal government and...
